The Global Covid -19 Vaccines Market was valued at 57 billion in 2020 and was expected to reach USD 86.4 billion by 2027, at a CAGR of 9.8%.
Currently in Global 150 coronavirus vaccines are in development process. The World Health Organization is also coordinating global efforts to develop a vaccine, with an eye toward delivering two billion doses by the end of 2021.
Major players in the market are Pfizer, BioNtech, University Of Oxford, Sinovac, Moderna Therapeutics, Gamaleya National Centers, Bharat Biotech, NovaVax, Johnson & Johnson and Sinopharm.
On November 20-Pfizer and BioNTech were together filing for emergency authorization from the FDA just two days after announcing the conclusion of their phase three trials of BNT162b2 vaccine. The companies stated that they’ve met their primary goals: The analysis found the candidate to be 95 percent effective in preventing mild and serious cases of COVID-19—and 94 percent effective in adults over 65 years old—with no serious safety concerns. Pfizer expects to be able to produce up to 50 million vaccine doses in 2020 and 1.3 billion doses by the end of 2021.
On November 18, Oxford’s Research team has transferred the SARS-CoV-2 spike protein—which helps the coronavirus invade cells preliminary results from Oxford’s phase two trials showing that the vaccine produced strong immune responses across all adult age groups, including older adults who are more vulnerable to the disease. Early results also revealed that the vaccine had triggered a strong immune response including increased antibodies and responses from T cells with only minor side effects such as fatigue and headache.
On November 17, Sinovac’s early trials, reported that the vaccine was safe but produced only a moderate immune response, with lower levels of antibodies compared to those in patients who have recovered from COVID-19. CoronaVac entered phase three trials in July, with plans to recruit nearly 9,000 healthcare professionals in Brazil, in addition to phase three trials in Indonesia and Bangladesh.
Moderna invent mRNA vaccine which relies on injecting snippets of mRNA into human cells to trigger an immune response. Moderna started the third phase of its clinical trials in July 2020. Preliminary findings from its phase one trials showed that including elderly patients—produced coronavirus antibodies and a reaction from T cells, another part of the human immune response. Phase three is testing the vaccine in 30,000 U.S. participants; Moderna expects to have 20 million doses ready to ship in the U.S. by the end of the year and says it remains on track to deliver at least 500 million doses per year beginning in 2021,
On September 24, Novavax announced the launch of its phase three trial in the United Kingdom, which will evaluate the vaccine in up to 10,000 people, both with and without underlying conditions. Novavax launching NVX-CoV2373 vaccine Up to 400 participants will also be vaccinated against the seasonal flu as part of a sub-study that will help determine whether it is safe to give patients both vaccines at the same time.
Market Segmentation of Covid-19 Market is divided on the basis of type, application and region. By type it has splits into DNA, Non-replicating Viral Vector, Protein Subunit and RNA. By Application it has been Hospitals, Research Center and etc. By Region it has segmented into Asia-Pacific, North America, Europe, Middle East & Africa and Latin America. U.S. government’s Operation Warp Speed initiative, which has pledged $10 billion and aims to develop and deliver 300 million doses of a safe, effective coronavirus vaccine by January 2021. North America is gaining to account for the highest number of revenue shares of the global coronavirus vaccine market in the 2020 & coming years, followed by the markets in Europe. This has happened due to the applying advanced technology and R & D activities. After that Asia will come at highest revenue shares in a forecast period by rapidly producing vaccines for covid.
For more information contact @